Adenosine Monophosphate

"Adenosine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.

Descriptor ID	D000249
MeSH Number(s)	D03.633.100.759.646.138.180 D13.695.667.138.180 D13.695.827.068.180
Concept/Terms	Adenosine Monophosphate Adenosine Monophosphate AMP Adenosine 5'-Phosphate Adenosine 5'-Phosphate 5'-Phosphate, Adenosine Adenosine 5' Phosphate Adenosine Phosphate Dipotassium Adenosine Phosphate Dipotassium Dipotassium, Adenosine Phosphate Phosphate Dipotassium, Adenosine Adenosine Phosphate Disodium Adenosine Phosphate Disodium Disodium, Adenosine Phosphate Phosphate Disodium, Adenosine Adenosine 2'-Phosphate Adenosine 2'-Phosphate Adenosine 2' Phosphate 2'-Adenylic Acid 2'-Adenylic Acid 2' Adenylic Acid Acid, 2'-Adenylic 2'-Adenosine Monophosphate 2' Adenosine Monophosphate Monophosphate, 2'-Adenosine Adenylic Acid 2'-AMP 5'-Adenylic Acid 5'-Adenylic Acid 5' Adenylic Acid Acid, 5'-Adenylic Adenosine 3'-Phosphate Adenosine 3'-Phosphate Adenosine 3' Phosphate Phosphaden Phosphaden

Below are MeSH descriptors whose meaning is more general than "Adenosine Monophosphate".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Purines [D03.633.100.759]
Purine Nucleotides [D03.633.100.759.646]
Adenine Nucleotides [D03.633.100.759.646.138]
Adenosine Monophosphate [D03.633.100.759.646.138.180]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleotides [D13.695]
Purine Nucleotides [D13.695.667]
Adenine Nucleotides [D13.695.667.138]
Adenosine Monophosphate [D13.695.667.138.180]
Ribonucleotides [D13.695.827]
Adenine Nucleotides [D13.695.827.068]
Adenosine Monophosphate [D13.695.827.068.180]

Below are MeSH descriptors whose meaning is related to "Adenosine Monophosphate".

Below are MeSH descriptors whose meaning is more specific than "Adenosine Monophosphate".

Adenosine Monophosphate
Adenosine Phosphosulfate

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adenosine Monophosphate" by people in this website by year, and whether "Adenosine Monophosphate" was a major or minor topic of these publications.

Bar chart showing 33 publications over 19 distinct years, with a maximum of 5 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	0	1	1
1998	0	1	1
1999	1	0	1
2002	1	0	1
2003	1	0	1
2004	2	0	2
2005	0	1	1
2006	1	2	3
2007	0	1	1
2008	0	1	1
2012	0	1	1
2013	1	1	2
2014	1	2	3
2018	1	0	1
2019	1	0	1
2020	3	0	3
2021	3	2	5
2022	0	3	3

Below are the most recent publications written about "Adenosine Monophosphate" by people in Profiles.

Potter GE, Bonnett T, Rubenstein K, Lindholm DA, Rapaka RR, Doernberg SB, Lye DC, Mularski RA, Hynes NA, Kline S, Paules CI, Wolfe CR, Frank MG, Rouphael NG, Deye GA, Sweeney DA, Colombo RE, Davey RT, Mehta AK, Whitaker JA, Castro JG, Amin AN, Colombo CJ, Levine CB, Jain MK, Maves RC, Marconi VC, Grossberg R, Hozayen S, Burgess TH, Atmar RL, Ganesan A, Gomez CA, Benson CA, Lopez de Castilla D, Ahuja N, George SL, Nayak SU, Cohen SH, Lalani T, Short WR, Erdmann N, Tomashek KM, Tebas P. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022 12; 175(12):1716-1727.

View in: PubMed
Paules CI, Gallagher SK, Rapaka RR, Davey RT, Doernberg SB, Grossberg R, Hynes NA, Ponce PO, Short WR, Voell J, Wang J, Yang OO, Wolfe CR, Lye DC, Dodd LE, Benson CA. Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. Clin Infect Dis. 2022 04 09; 74(7):1260-1264.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3). Ann Intern Med. 2022 05; 175(5):W55-W57.

View in: PubMed
Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, Kojic EM, Hirshberg A, Suarez JF, Sobieszczyk ME, Marks KM, Mazur S, Big C, Manuel O, Morlin G, Rose SJ, Naqvi M, Goldfarb IT, DeZure A, Telep L, Tan SK, Zhao Y, Hahambis T, Hindman J, Chokkalingam AP, Carter C, Das M, Osinusi AO, Brainard DM, Varughese TA, Kovalenko O, Sims MD, Desai S, Swamy G, Sheffield JS, Zash R, Short WR. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clin Infect Dis. 2021 12 06; 73(11):e3996-e4004.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Miller MC, Forciea MA, Humphrey LL. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 12; 174(12):W116-W117.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Miller MC, Forciea MA, Humphrey LL, Dunn A, Andrews R, Haeme R, Tschanz MP. Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 09; 174(9):W66-W67.

View in: PubMed
Coppock D, Baram M, Chang AM, Henwood P, Kubey A, Summer R, Zurlo J, Li M, Hess B. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS One. 2021; 16(6):e0252591.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL, Centor RM, Andrews R, Haeme R. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 05; 174(5):673-679.

View in: PubMed
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, F?tkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 11 05; 383(19):1813-1826.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL, Centor RM, Andrews R, Haeme R, Kansagara DL, Marcucci M. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2021 02; 174(2):229-236.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement